A real-world study of the efficacy and safety of Eribulin in different subtypes of advanced breast cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048468

Enrollment

Unknown

Registered

2021-07-09

Start date

2021-06-25

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:Eribulin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Advanced breast cancer patients aged older than 18 years; 2. The researchers believe that it is suitable for eribulin treatment; 3. The expected survival period is more than 3 months; 4. There are traceable medical history records during treatment.

Exclusion criteria

Exclusion criteria: 1. The patient cannot understand the study and is unwilling to sign the informed consent; 2. Pregnant or lactating patients; 3. Patients who were assessed by the researchers as not suitable for this study.

Design outcomes

Primary

Measure	Time frame
objective remission rate;progression free survival;overall survival;adverse event;disease control rate;clinical benefit rate;	—

Countries

China

Contacts

Public ContactLi Huihui

Shandong Cancer Hospital

15553103209@163.com+86 15553103209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026